# Dossier: GENECAPTURE, INC.

## SBIR Award Details

**Award Title:** N/A

**Amount:** $249,938.77

**Award Date:** 2024-02-02

**Branch:** DHA

## AI-Generated Intelligence Summary

**Company Overview:**

GeneCapture, Inc. is a diagnostic company developing rapid, point-of-care diagnostic platforms for infectious disease detection and identification. Their core mission is to enable faster, more accurate, and more accessible diagnostic testing, particularly in resource-limited settings and at the point of care. The company aims to solve the problem of slow and complex laboratory-based diagnostics, which can delay treatment and exacerbate outbreaks. GeneCapture's unique value proposition lies in its single-use, disposable cartridge technology which dramatically reduces turnaround time and simplifies the testing process, enabling near-real-time results at the bedside or in the field.

**Technology Focus:**

* GeneCapture's core technology is a microfluidic, single-use cartridge system that captures, concentrates, and identifies pathogens from bodily fluids (e.g., blood, saliva) in approximately 30 minutes.
* The system utilizes a novel capture technology that concentrates target analytes, enabling high sensitivity detection even with low pathogen loads. The system can be customized to detect multiple pathogens simultaneously.

**Recent Developments & Traction:**

* In September 2021, GeneCapture announced a $2.8 million Phase II Small Business Innovation Research (SBIR) contract with the U.S. Army Medical Research and Development Command (USAMRDC) to continue the development of their point-of-care diagnostic system for detecting biothreat agents.
* In 2022, GeneCapture completed the development and testing of a prototype device for detecting multiple respiratory pathogens, including SARS-CoV-2, influenza A, and influenza B.
* In 2023, GeneCapture showcased advancements of their technology at several industry events.

**Leadership & Team:**

* John Lowe, CEO. Prior experience includes leadership roles in medical device and diagnostic companies.
* Dr. Krishna Pothukuchi, Chief Science Officer. Dr. Pothukuchi has extensive experience in microfluidics and diagnostics.

**Competitive Landscape:**

* BioFire Diagnostics (now a part of bioMérieux): While BioFire offers comprehensive multiplex PCR-based diagnostic panels, GeneCapture's key differentiator is its focus on a highly rapid, point-of-care, single-use cartridge format intended for true field deployment without requiring a highly trained technician.
* Cepheid (acquired by Danaher): Cepheid's GeneXpert system offers rapid PCR-based diagnostics, but it is a larger, more complex system than GeneCapture's, making GeneCapture's disposable cartridge more attractive for resource-limited and mobile applications.

**Sources:**

* [https://www.genecapture.com/](https://www.genecapture.com/)
* [https://www.army.mil/article/250102/army\_awards\_2\_8m\_contract\_to\_alabama\_company\_to\_develop\_point\_of\_care\_diagnostic](https://www.army.mil/article/250102/army\_awards\_2\_8m\_contract\_to\_alabama\_company\_to\_develop\_point\_of\_care\_diagnostic)
* [https://sbir.defensebusiness.org/](https://sbir.defensebusiness.org/) (Search for GeneCapture in the database to verify SBIR awards)